Who
Manasi Jaiman
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Aardvark Therapeutics.
In numbers
- Trades disclosed
- 3
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Jun 2025
- Last trade
- 9 Feb 2026
- Last filed
- 11 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Feb 2026filed 11 Feb 2026 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,549 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,549 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | AARD Aardvark Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —126,999 at $0.00 | filing |
News
Caspian Therapeutics Appoints Manasi Jaiman, M.D., M.P.H., and Elizabeth Mily to Board of Directorsmanilatimes.net · 1 Oct 2026
1 headline in the last 90 days name Manasi Jaiman; no company of theirs resolves to a name we track.
Sectors
No trade we could place in a sector.